Correlates of Neutralization against SARS-CoV-2 Variants of Concern by Early Pandemic Sera

Samuel J. Vidal, a,b Ai-ris Y. Collier, a,c Jingyou Yu, a Katherine McMahan, a Lisa H. Tostanoski, a John D. Ventura, a Malika Aid, a Lauren Peter, a Catherine Jacob-Dolan, a,d Tochi Anioke, a Aiquan Chang, a,e Huahua Wan, a Ricardo Aguayo, c Debby Ngo, f Robert E. Gerszten, f Michael S. Seaman, a Dan H. Barouch a,g,h

aCenter for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
bDivision of Infectious Diseases, Massachusetts General Hospital and Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
cDepartment of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
dHarvard Medical School, Boston, Massachusetts, USA
eProgram in Immunology, Harvard Medical School, Boston, Massachusetts, USA
fDivision of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
gRagon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA
hMassachusetts Consortium on Pathogen Readiness, Boston, Massachusetts, USA

Samuel J. Vidal and Ai-ris Y. Collier contributed equally to this work. Author order was determined by experimentation and manuscript writing.

ABSTRACT
Emerging SARS-CoV-2 variants of concern that overcome natural and vaccine-induced immunity threaten to exacerbate the COVID-19 pandemic. Increasing evidence suggests that neutralizing antibody (NAb) responses are a primary mechanism of protection against infection. However, little is known about the extent and mechanisms by which natural immunity acquired during the early COVID-19 pandemic confers cross-neutralization of emerging variants. In this study, we investigated cross-neutralization of the B.1.1.7 and B.1.351 SARS-CoV-2 variants in a well-characterized cohort of early pandemic convalescent subjects. We observed modestly decreased cross-neutralization of B.1.1.7 but a substantial 4.8-fold reduction in cross-neutralization of B.1.351. Correlates of cross-neutralization included receptor binding domain (RBD) and N-terminal domain (NTD) binding antibodies, homologous NAb titers, and membrane-directed T cell responses. These data shed light on the cross-neutralization of emerging variants by early pandemic convalescent immune responses.

IMPORTANCE
Widespread immunity to SARS-CoV-2 will be necessary to end the COVID-19 pandemic. NAb responses are a critical component of immunity that can be stimulated by natural infection as well as vaccines. However, SARS-CoV-2 variants are emerging that contain mutations in the spike gene that promote evasion from NAb responses. These responses may therefore delay control of the COVID-19 pandemic. We studied whether NAb responses from early COVID-19 convalescent patients are effective against the two SARS-CoV-2 variants, B.1.1.7 and B.1.351. We observed that the B.1.351 variant demonstrates significantly reduced susceptibility to early pandemic NAb responses. We additionally characterized virological, immunological, and clinical features that correlate with cross-neutralization. These studies increase our understanding of emerging SARS-CoV-2 variants.

KEYWORDS
SARS-CoV-2, T cells, neutralizing antibodies

The COVID-19 pandemic has resulted in more than 110 million infections and 2.5 million deaths worldwide (1). Accumulating evidence suggests that both natural (2, 3) and vaccine-induced (4–7) immunity strongly protects from SARS-CoV-2. However, the emergence of novel SARS-CoV-2 variants with diverse mutations threatens to

Citation Vidal SJ, Collier A-RY, Yu J, McMahan K, Tostanoski LH, Ventura JD, Aid M, Peter L, Jacob-Dolan C, Anioke T, Chang A, Wan H, Aguayo R, Ngo D, Gerszten RE, Seaman MS, Barouch DH. 2021. Correlates of neutralization against SARS-CoV-2 variants of concern by early pandemic sera. J Virol 95:e00404-21. https://doi.org/10.1128/JVI.00404-21.
Editor Julie K. Pfeiffer, University of Texas Southwestern Medical Center
Copyright © 2021 Vidal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.
Address correspondence to Dan H. Barouch, dbarouch@bidmc.harvard.edu.
Received 7 March 2021
Accepted 20 April 2021
Accepted manuscript posted online 28 April 2021
Published 24 June 2021
attenuate the magnitude of these mechanisms of immunity (8). Adoptive transfer (9) and vaccine studies (10) in rhesus macaques suggest that neutralizing antibody (NAb) responses are a critical correlate of protection against SARS-CoV-2 infection. Therefore, the extent to and mechanisms by which early pandemic convalescent-phase sera cross-neutralize emerging variants is an important area of investigation.

The first major SARS-CoV-2 mutation to be extensively characterized was D614G, which began to emerge in April 2020. Epidemiological and virological studies suggest that D614G exhibits increased replicative capacity (11–13) while also conferring increased cross-neutralization by vaccine-induced mouse and monkey antibody responses as well as convalescent human responses (14). Subsequently, reports began to emerge in the United Kingdom in December 2020 regarding the B.1.1.7 variant that contains 8 spike mutations in addition to D614G (15). As-yet unpublished reports suggest that the N501Y mutation located in the receptor binding domain (RBD) may increase its affinity to the angiotensin-converting enzyme 2 (ACE2) receptor (16), while the Δ69-to-70 deletion in the N-terminal domain (NTD) may increase SARS-CoV-2 infectivity (17). Clinically, the B.1.1.7 variant is associated with increased viral loads (18). In addition, reports began to emerge in South Africa in December 2020 regarding the B.1.351 variant that contains 9 spike mutations in addition to D614G. These involve clusters of mutations in the RBD and NTD, including the K417N and E484K mutations that promote neutralization resistance (19–21). Other B.1.1.7 and B.1.351 spike mutations are presently of uncertain significance.

Published and as-yet unpublished reports are emerging regarding the cross-neutralizing potential of clinically relevant monoclonal antibodies and vaccine-induced responses. mRNA-1273 (21, 22) and BNT162b2 (21, 23) vaccine-induced sera showed efficient cross-neutralization of B.1.1.7. In contrast, mRNA-1273 (21, 22) and BNT162b2 (21, 24) vaccine-induced sera showed ~3- to 8-fold reductions in cross-neutralization of B.1.351. The REGN-COV2 antibody cocktail showed a ~10-fold reduction in cross-neutralization of B.1.351 in one unpublished report (25). In another unpublished report, REGN-COV2 retained cross-neutralization of B.1.351, while LY-CoV555 showed a >100-fold reduction in 50% inhibitory concentration (IC50) (21).

Additional emerging reports suggest 1- to 4-fold and 3- to 30-fold reductions in the neutralization of B.1.1.7 and B.1.351, respectively, by early COVID-19 pandemic convalescent-phase sera (21, 26, 27). However, overall, little is known about the extent and mechanisms by which natural immunity acquired during the early COVID-19 pandemic confers cross-neutralization of emerging variants. In the present study, we examined these questions in a well-characterized cohort of early COVID-19 pandemic convalescent subjects.

RESULTS

Early COVID-19 pandemic convalescent cohort and prepandemic controls. We identified 21 patients admitted to Beth Israel Deaconess Medical Center (BIDMC; Boston, MA, USA) between April and June of 2020 for symptoms related to COVID-19 (Table 1). All patients had a documented positive SARS-CoV-2 nasopharyngeal nucleic acid amplification test at admission. Ages ranged from 33 to 94 (median age 68), and there were 11 females and 10 males. Comorbidity numbers ranged from 0 to 5 (median, 3). Hospital stay ranged from 2 to 34 days (median stay, 15 days). Twenty out of twenty-one patients developed severe COVID-19 by World Health Organization criteria (peripheral oxygen saturation [SpO2] < 94%), and among these, 10 patients required intubation. Serum and peripheral blood mononuclear cells (PBMCs) were obtained within 2 days of discharge and after resolution or near resolution of presenting symptoms. We additionally obtained serum and PBMCs from 8 archival adult prepandemic controls.

Characterization of an early pandemic cohort with Wuhan strain sequences. We initially characterized our convalescent COVID-19 cohort using early pandemic (Wuhan strain) detection reagents. We first characterized binding antibody responses by enzyme-linked immunosorbent assay (ELISA) using strain-specific RBD coating

Vidal et al. Journal of Virology July 2021 Volume 95 Issue 14 e00404-21 jvi.asm.org
antigens from SARS-CoV-2 as well as the common endemic coronaviruses HKU1, OC43, and 229E. We observed robust SARS-CoV-2 binding responses in all COVID-19 individuals except participant 14, a 90-year-old man with multiple comorbidities (Fig. 1A). In contrast, all endemic coronaviruses demonstrated similar RBD IgG ELISA titers between prepandemic and convalescent COVID-19 subjects (Fig. 1B).

In order to gain greater epitope specificity among binding antibody responses, we next used a multiplexed electrochemiluminescence assay (ECLA; Meso Scale Discovery) to measure responses to full-length SARS-CoV-2 spike, RBD, NTD, and nucleocapsid. All COVID-19 patients demonstrated reactivity greater than prepandemic controls to full-length spike (Fig. 1C). Responses to RBD and NTD were comparable in frequency, with only participant 14 showing signal similar to prepandemic controls (Fig. 1C). Moreover, most patients also demonstrated binding antibody responses to nucleocapsid (Fig. 1C). Overall, this antibody binding epitope distribution was comparable to previous studies of convalescent individuals (28). RBD IgG responses measured by ELISA and ECLA were strongly correlated (Fig. 1D), and therefore, going forward, we used multiplexed ECLA binding data in our analyses.

We next assessed NAb responses in an assay employing a recombinant lentiviral pseudovirus expressing the Wuhan SARS-CoV-2 spike sequence and HEK293T target cells ectopically expressing the human ACE2 receptor (HEK293T-hACE2). We observed responses above prepandemic controls among all but one convalescent COVID-19 subjects (Fig. 2A). The frequency and magnitude of NAb responses were consistent with recent large cohort studies of convalescent individuals (29, 30). NAb responses correlated most strongly with both RBD and NTD binding antibody responses (Fig. 2B). A significant but less robust correlation between NAb responses and nucleocapsid binding antibody responses was unsurprising given that this antigen is presumably not a target for NABs and likely serves as a marker of antibody responses (Fig. 2B).

### Table 1: Early pandemic convalescent COVID-19 inpatient cohort clinical data

| Patient no. | Age (yrs) | Gender | Major comorbidity(ies)                                                                 | Admission duration (no. of days) | Location of peak oxygen requirement |
|-------------|-----------|--------|--------------------------------------------------------------------------------------|----------------------------------|-------------------------------------|
| 1           | 70        | M      | Degenerative joint disease                                                            | 6                                | Nasal cannula                       |
| 2           | 59        | F      | Hypertension, diabetes mellitus, deep vein thrombosis                                 | 5                                | Nasal cannula                       |
| 3           | 69        | F      | Obesity, hypertension, diabetes mellitus, obstructive sleep apnea, rheumatoid arthritis | 34                               | Intubated                           |
| 4           | 59        | F      | Obesity, hypertension                                                                 | 4                                | Nasal cannula                       |
| 5           | 68        | F      | Pulmonary embolus, sarcoidosis on prednisone, hypothyroidism, stroke                  | 25                               | Intubated                           |
| 6           | 39        | M      | None                                                                                  | 20                               | Intubated                           |
| 7           | 68        | M      | Diabetes mellitus                                                                     | 32                               | Intubated                           |
| 8           | 82        | M      | Stroke, cognitive impairment, seizure                                                 | 14                               | Nasal cannula                       |
| 9           | 80        | F      | Hypertension, breast cancer on hormonal therapy, cognitive impairment                 | 6                                | Room air                            |
| 10          | 77        | M      | Hypertension, diabetes mellitus, cognitive impairment                                 | 33                               | Intubated                           |
| 11          | 50        | F      | Obesity, diabetes mellitus                                                            | 25                               | Intubated                           |
| 12          | 73        | M      | Hypertension, diabetes mellitus, cognitive impairment                                 | 12                               | Nasal cannula                       |
| 13          | 81        | M      | Hypertension, diabetes mellitus                                                       | 25                               | Intubated                           |
| 14          | 90        | M      | Arrhythmia, chronic obstruction pulmonary disease, chronic kidney disease, cognitive impairment | 15                               | Nasal cannula                       |
| 15          | 66        | F      | Reactive airway disease                                                               | 34                               | Intubated                           |
| 16          | 57        | F      | Hypertension, diabetes mellitus, muscular dystrophy                                  | 11                               | Nasal cannula                       |
| 17          | 33        | F      | Obesity, reactive airway disease                                                     | 5                                | Nasal cannula                       |
| 18          | 94        | F      | Hypertension, arrhythmia                                                             | 2                                | Nasal cannula                       |
| 19          | 84        | M      | Hypertension, diabetes mellitus, Parkinson disease                                   | 9                                | Nasal cannula                       |
| 20          | 54        | F      | Obesity, hypertension, diabetes mellitus, obstructive transplant on multimodal immunosuppression | 32                               | Intubated                           |
| 21          | 57        | M      | Hypertension, diabetes mellitus, coronary artery disease, renal transplant on multimodal immunosuppression | 32                               | Intubated                           |

*Early pandemic convalescent COVID-19 inpatient (n = 21) data, including age, gender, major comorbidities, admission duration, and peak oxygen requirement.
To characterize T cell responses, we performed interferon gamma (IFN-γ) enzyme-linked immune absorbent spot (ELISPOT) assays with the convalescent COVID-19 cohort and prepandemic controls. We focused on the 9 structural and accessory proteins that account for approximately 75% of the CD4 and CD8 T cell responses to SARS-CoV-2 infection (31). We observed ELISPOT responses among all convalescent patients, primarily against the SARS-CoV-2 spike, membrane, and nucleocapsid proteins (Fig. 3A). This pattern of immunodominance was consistent with a previous report that assessed T cell responses by flow cytometry (31). Moreover, similar to prior reports (31–33), aggregate T cell responses correlated with spike RBD and NTD binding (Fig. 3B) as well as NAb (Fig. 3C) responses. We observed a trend toward correlation between aggregate T cell responses and nucleocapsid binding antibodies \((P = 0.067, R = 0.43; \text{two-sided Spearman rank correlation test})\).

![FIG 1 SARS-CoV-2 and endemic coronavirus binding antibody responses among early pandemic convalescent COVID-19 inpatients and prepandemic controls. (A) SARS-CoV-2 spike RBD IgG ELISA titers. (B) HKU1, OC43, and 229E spike RBD IgG ELISA titers. (C) Full-length spike, spike RBD, and spike NTD IgG ECLA signals. (D) Spearman correlation between SARS-CoV-2 spike RBD IgG ELISA titer and ECLA signal. Bars represent geometric means. Dotted lines represent limits of detection (LOD) for ELISA and lower limits of detection (LLOD) for ECLA. Convalescent COVID-19 inpatient and prepandemic subjects were compared by Mann-Whitney test.](image-url)
NAb responses to emerging SARS-CoV-2 variants in early pandemic sera. In order to assess NAb responses to emerging SARS-CoV-2 variants by early pandemic sera, we next constructed pseudoviruses containing the B.1.1.7 and B.1.351 spike sequences for neutralization assays. We additionally constructed a pseudovirus containing only D614G since this spike variant is now ubiquitous and was previously shown to exhibit increased cross-neutralization by early pandemic convalescent-phase serum (11, 12, 14). Indeed, we observed a modest though nonsignificant increase in the neutralization geometric mean titer (GMT) of D614G among 17/20 subjects with detectable Wuhan NAb titers (average, 1.5-fold increase; range, 0.8 to 2.8; Fig. 4A). In contrast, B.1.1.7 showed a modest though nonsignificant decrease in pseudovirus neutralization among 13/20 subjects with detectable Wuhan NAb titers (average, 1.5-fold decrease; range, 0.5 to 2.9; Fig. 4A). Notably, B.1.351 showed a significant reduction in pseudovirus neutralization among 19/20 subjects with detectable Wuhan NAb titers (average, 4.8-fold decrease; range, 0.4 to 14.8; Fig. 4A). Reductions in B.1.351 cross-neutralization were generally uniform, and the 2/20 patients with newly undetectable B.1.351 NAb titers had low baseline Wuhan titers (Fig. 4B). Notably, individuals with Wuhan NAb titers as high as 295 developed undetectable B.1.351 cross-neutralization titers.

Correlates of emerging SARS-CoV-2 variant cross-neutralization. Given the number of clinical and immunological variables in our study, we next used unbiased bioinformatics approaches to analyze our results. We first performed unsupervised hierarchical clustering of patients and all of our continuous clinical, immunological, and virological variables (Fig. 5A). Hospital duration showed a strong association with intubation in our cohort. Average stays were 8.1 and 28.6 days among nonintubated and intubated individuals, respectively ($P = 4.4 \times 10^{-9}$; Student’s $t$ test). We therefore used this continuous variable as a surrogate for disease severity in our computational

![Graphs showing neutralization against SARS-CoV-2 Variants of Concern](https://example.com/graphs.png)
analyses. We observed that individuals with strong SARS-CoV-2-specific humoral and cellular responses formed a large cluster. Interestingly, this cluster also contained hospital duration, was associated with intubation ($P = 0.03$; Fisher’s exact test), and segregated into distinct groups of humoral or cellular immune responses (Fig. 5A).

To gain insights into the correlates of both Wuhan strain neutralization and variant cross-neutralization by early pandemic sera, we assembled a correlogram incorporating the same variables used in our heat map (Fig. 5B). Unsupervised hierarchical clustering revealed a group of highly correlated features that exclusively included binding and NAb responses to SARS-CoV-2. Other than NAb responses to Wuhan, D614G, and B.1.1.7, NAb responses to B.1.351 showed the strongest correlations with Wuhan full-length spike, RBD, and NTD IgG binding antibody responses. These data suggest that baseline Wuhan spike binding and NAb responses may be the most important correlates of B.1.351 cross-neutralization. Moreover, several of the SARS-CoV-2 antibody responses correlated with disease severity as well as with ELISPOT responses. Interestingly, among cellular responses, we observed that membrane-specific responses exhibit the strongest correlations with binding and NAb responses. Finally, we observed that antibody responses to the RBD of pre-COVID-19 endemic coronaviruses showed no correlation with SARS-CoV-2 immune responses in our study.

**DISCUSSION**

Little is known about the extent and mechanisms by which natural immunity acquired during the early COVID-19 pandemic confers cross-neutralization of emerging variants. In the present study, we examined these questions in a well-characterized cohort of early COVID-19 pandemic convalescent subjects. We observed modest reductions in cross-neutralization of B.1.1.7 and significant reductions in cross-neutralization of B.1.351. Correlates of cross-neutralization included RBD and NTD binding and spike NAb responses as well as membrane glycoprotein-directed T cell responses. These
data shed light on cross-neutralization of emerging variants by early pandemic immune responses.

Given the recent emergence of B.1.1.7 and B.1.351, the cross-neutralization of these variants by early pandemic sera has yet to be firmly established. An initial study (21) employed a vesicular stomatitis virus pseudovirus assay with Vero cells and a combination of nonsevere and severe COVID-19 convalescent-phase sera to report 2.7- to 3.8-fold reductions in cross-neutralization of B.1.1.7 and 11- to 33-fold reductions in cross-neutralization of B.351. A second unpublished report (26) using authentic virus with Vero-hACE2-TMPRSS2 cells and mild COVID-19 convalescent-phase sera found a 4.5-fold reduction in cross-neutralization of B.1.351. A third study using authentic virus with Vero cells and severe COVID-19 sera at various stages of convalescence reported 2.1- to 4.8-fold reductions in cross-neutralization of B.351. We used a lentiviral pseudovirus assay with HEK293T-hACE2 cells and a relatively homogeneous group of convalescent-phase sera following hospitalization for severe COVID-19 to report a 4.8-fold average reduction in cross-neutralization of B.351. Variability in the degree of cross-neutralization among recent studies and our data may be explained by differences in neutralization assays as well as clinical heterogeneity among study populations, though further studies are needed to establish consistent trends. Nonetheless, these data collectively suggest significant reductions but not complete effacement of B.1.351 neutralization by early pandemic convalescent-phase sera. Finally, mRNA-1273 (18, 19) and BNT162b2 (18, 21) vaccine-induced sera showed 3-8-fold reductions in cross-neutralization of B.1.351.

Our correlates analysis suggests that the most important predictor of Wuhan, as well as variant neutralization, may be high levels of both RBD and NTD baseline binding antibody responses. These findings both affirm the critical role of the RBD in NAb responses and corroborate a growing literature highlighting the importance of the NTD as a target (28, 34–36). Moreover, binding and NAb responses were associated with hospital duration and intubation, corroborating a now large literature linking disease severity with increased adaptive immune responses (28, 37–41). Consistent with previous reports, binding and NAb responses correlated with T cells responses (31–33). Interestingly, we observed that membrane-specific ELISPOT responses showed the strongest correlation with antibody responses. This might be explained by the finding that the spike- and nucleocapsid-specific T cell pools contain a significant proportion of cross-reactive T cell responses derived from prepandemic coronavirus infections (42, 43), although further studies with larger numbers of patients are necessary to clarify this phenomenon.
FIG 5 Correlates of emerging variant cross-neutralization by early pandemic convalescent-phase sera. (A) Heat map with unsupervised hierarchical clustering of clinical, virological, and immunological
(Continued on next page)
We reported that IgG derived from convalescent rhesus macaques previously challenged with Washington (USA-WA1) strain SARS-CoV-2 can confer protection from homologous challenge after adoptive transfer into naive monkeys (9). Using a dose escalation scheme and logistic regression analysis, we estimated that a homologous NAb titer of approximately 50 protected from infection. In addition to the 2 patients with baseline Wuhan NAb titers who showed newly undetectable B.1.351 cross-neutralization titers, an additional two subjects showed B.1.351 cross-neutralization titers below this threshold (Fig. 4B). Although our prior protection data were obtained in rhesus macaques lacking SARS-CoV-2-specific T cells and challenged with Washington strain, these data suggest that a fraction of early pandemic convalescent individuals may exhibit subprotective B.1.351 cross-neutralization titers.

In summary, we report the cross-neutralization of emerging SARS-CoV-2 variants of concern by early pandemic sera. Our data support significant reductions but not complete effacement of B.1.351 cross-neutralization, and we report that RBD and NTD binding and spike NAb responses, as well as membrane-directed T cell responses, are correlates of cross-neutralization. These data expand our understanding of emerging SARS-CoV-2 variants that threaten to exacerbate the COVID-19 pandemic.

MATERIALS AND METHODS

Patient enrollment. Participants were enrolled under the Beth Israel Deaconess Medical Center (BIDMC) COVID-19 Tissue and Data Repository (IRB 2020P00361) between April and June 2020. Eligible participants were 18 years or older and able to provide informed consent or have a legal authorized representative consent on their behalf. All electronic health records (EHRs) were reviewed by an infectious diseases physician. Comorbidities and admission absolute lymphocyte counts (ALCs) were determined on the basis of admitting physician notes, and all other reported clinical details were determined from the EHR as appropriate. We identified eight archival prepandemic adult subjects from unrelated studies in our laboratory as controls.

Enzyme-linked immunosorbent assay. ELISA plates (Thermo Fisher) were coated with spike receptor binding domain (RBD) protein and stored overnight at 4°C. All ELISA proteins were synthesized at the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard. Plates were then blocked, and serially diluted serum samples were added to each well. Following sample incubation, plates were washed with Dulbecco’s phosphate-buffered saline (DPBS)-TWEEN, and horseradish peroxidase (HRP)-conjugated goat anti-human immunoglobulin secondary antibodies of the indicated isotype specificity were added (IgG [Invitrogen], IgA [Bethyl], and IgM [Invitrogen]). Plates were washed, developed with KPL TMB peroxidase, the reaction was halted with KPL TMB stop solution, and absorbance was recorded using a VersaMax microplate reader.

Multiplexed electrochemiluminescence assay. ECLA plates (Meso Scale Discovery; SARS-CoV-2 panel 2 [IgG kit]) were incubated with blocking buffer for 30 min followed by serum diluted at 1:25,000 and 1:125,000 for 2 h. Plates were then washed and incubated with secondary antibody (Sulfo-Tag anti-human IgG antibody) for 1 h. Plates were washed again and incubated in read buffer, and luminescence was detected on a Meso Sector S 600 microplate reader. Plates were run with manufacturer-provided serially diluted stock controls. Serum dilution was selected when luminescence data were contained with the linear range of the standard curve, which was used to calculate arbitrary units per milliliter. Lower limits of detection were calculated by fitting 2.5 standard deviations above the zero calibrator to the standard curve for each individual plate.

Pseudovirus neutralization assay. A lentiviral pseudovirus expressing a luciferase reporter gene was generated as previously described (10). Briefly, packaging plasmid psPAX2 (AIDS Resource and Reagent Program), luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein-expressing pCDNA3.1-SARS-CoV-2 5ΔCT sequences for the Wuhan, D614G, B.1.1.7, and B.1.351 strains were cotransfected into HEK293T cells by Lipofectamine 2000 (Thermo Fisher). Supernatant was collected 48 h posttransfection. HEK293T-hACE2 cells were seeded in 96-well plates at a density of 1.75 × 10^4 cells per well overnight. Threefold serial dilutions of heat-inactivated serum samples were prepared and mixed with 50 μl of pseudovirus. The mixture was incubated at 37°C for 1 h before adding to HEK293T-hACE2 cells. Forty-eight hours after infection, cells were lysed in Steady-Glo luciferase assay (Promega). SARS-CoV-2 neutralization titers were defined as the sample dilution at which a 50% reduction in relative light unit was observed relative to the average of the virus control wells.

IFN-γ enzyme-linked immune absorbent spot assay. White membrane plates (Millipore) were coated at 4°C overnight with 10 μg/ml anti-human IFN-γ (Mabtech). Peptides spanning the entire nonreplicate
SARS-CoV-2 genome were synthesized as 15mers overlapping by 11 residues, and peptides were organized into individual antigen pools for PBMC stimulation (JPT Peptide Technologies). Next, rest PBMCs were plated in duplicate at \(2 \times 10^{6}\) with peptide pools corresponding to individual SARS-CoV-2 proteins at 2\(\mu\)g/ml and 18 h at 37°C. Development was achieved by addition of biotin (Mabtech), anti-biotin (Vector Labs), and chromogen (Pierce). Background subtraction was performed using a matched 0.4% dimethyl sulfoxide (DMSO) control well.

### Statistical methods.

Pairwise comparisons of ELISA, ECLA, 50% neutralizing titer (NT_{50}), and ELISPOT clinical data were performed by Mann-Whitney test. Multigroup comparisons were performed by Kruskal-Wallis test. These tests, as well as pairwise Spearman correlations, were performed using GraphPad Prism 8 software. The heatmap was generated using the heatmap package in R, scaled by variable values, and clustered both by patient and by variable using default scaling and hierarchical clustering settings. For the correlogram, pairwise Spearman rank coefficients were calculated using the psych package v2.0.12 in R using the corr.test function with default settings and the adjust argument set to “fdr” to calculate adjusted \(P\) values using Benjamini-Hochberg correction for multiple comparisons. The resulting correlation matrix was visualized as a correlogram using the corrplot package in R. Spearman rank coefficients were ordered via hierarchical clustering by setting the order argument to “hclust” in the corrplot function.

### ACKNOWLEDGMENTS

We thank the study participants and their families. We are also grateful to the frontline health care providers and staff for their assistance with research sample collection and the frontline laboratory staff involved in processing samples for the COVID-19 Biorepository.

Screening and enrollment for the COVID-19 Biorepository were supported by the Department of Obstetrics and Gynecology, Nathan Shapiro from the Department of Emergency Medicine, and the office of Gyongyi Szabo.

We thank Laurie Farrell, Juwerna Quadir, Victoria Sitar, Alec Brown, Sabrina Tan, Lisa Kurt, Michael Bolstad, Sharon Hayes, Thomas O’Mara, Conor Higgins, and Jeanie Lee for patient screening and enrollment. Coordination of specimen collection and transport was provided by the Clinical Research Center staff. We thank the laboratory staff of Anjali Nath for processing, storage, and distribution of clinical samples. We thank Jim Wilbur and Jacob Wohlstader of Meso Scale Discovery for providing ECLA kits.

D.H.B. received support from the Massachusetts Consortium on Pathogen Readiness (MassCPR); the Ragon Institute of MGH, MIT, and Harvard; and the National Institutes of Health (OD024917, AI129797, AI124377, AI128751, AI126603, and CA260476). S.J.V. received support from the NIH Multidisciplinary AIDS Training Program grant T32 AI07387. A.Y.C. received support from MassCPR, grant K12 HD000849, awarded to the Reproductive Scientist Development Program by the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Burroughs Wellcome Fund, the BIDMC Department of Obstetrics and Gynecology, the Clinical Research Center supported by the Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, National Institutes of Health Award UL 1TR002541), and philanthropic support from the BIDMC Chief Academic Office.

### REFERENCES

1. Dong E, Du H, Gardner L. 2020. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20:533–534. https://doi.org/10.1016/S1473-3099(20)30120-1.

2. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Comalli RJ, Jones EY, Stuart DI, Screaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O’Donnell AM, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffrey K, Eyre DW, Oxford University Hospitals Staff Testing Group. 2021. Antibody status and incidence of SARS-CoV-2 infection in health care workers. N Engl J Med 384:533–540. https://doi.org/10.1056/NEJMoa2034545.

3. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, Meyer WA, III, Kaufman HW, Anderson S, Cohen O, Petkov V, Cronin KA, Van Dyke AL, Lowy DR, Sharpless NE, Penberthy LT. 2021. Association of SARS-CoV-2 infection, FLAIR immunoblot with risk of future infection. JAMA Intern Med https://doi.org/10.1001/jamainternmed.2021.0366.

4. Polack FP, Thomas SJ, Kitchin N, Absalon J, Guttmann A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, French RW, Jr., Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC, Group CCT, C4591001 Clinical Trial Group. 2020. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 383:2603–2615. https://doi.org/10.1056/NEJMoa2034577.

5. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Roupahaal N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, James H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. 2021. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med 383:403–416. https://doi.org/10.1056/NEJMoa2035389.

6. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Bamshad SL, Bhorat QE, Bibi S, Briner C, Ciconni P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Dunca CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Fengo S, Ferreira DM, Finn A,
Neutralization against SARS-CoV-2 Variants of Concern

Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch J, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliot A, Libi V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, Oxford COVID Vaccine Trial Group, et al. 2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397:99–111.

7. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaev AS, Kovyshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izaeva FM, Popova O, Ozhavoryashka TA, Esmagambetov IB, Favorskaya IA, Zelkin DL, Vonorina DV, Schcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Sharomov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zryazin SK, Borishevich SV, Naroditsky BS, Gintsburg AL, Gam-COVID-Vac Vaccine Trial Group. 2021. Neutralising activity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled trial. Lancet 397:671–681. https://doi.org/10.1016/S0140-6736(21)00234-8

8. Fontanet A, Autran B, Lina B, Kieny MP, Karim SSA, Sridhar D. 2021. SARS-CoV-2 variants: an update. J Virol 85:13227–13238.

9. McManahin K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, Peter L, Atyeo C, Zhu A, Bonder EA, Dagotto G, Gebres M, Jaggi DN, Edward RZ, Zan F, Patel S, Persaud V, Bayley D, Opstal Y, Blaise EJ. 2021. Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. bioRxiv 2021.10.01.447063.

10. Korber B, Frantzen G, Caradonna TM, Bhardwaj D, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N, Hengartner N, Giorgi EE, Bhattacharya T, Foley B, Haste AM, Lin Z, Lelliot A, Libri V, Lillie PJ, Mallory R, van Doremalen N.
structure-guided high-resolution serology. Cell 183:1024–1042.e21. https://doi.org/10.1016/j.cell.2020.09.037.

29. Wu F, Liu M, Wang A, Lu L, Wang Q, Gu C, Chen J, Wu Y, Xia S, Ling Y, Zhang Y, Xun J, Zhang R, Xie Y, Jiang S, Zhu T, Lu H, Wen Y, Huang J. 2020. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med 180:1356–1362. https://doi.org/10.1001/jamainternmed.2020.4616.

30. Wajnberg A, Amanat F, Frifo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, Stadtbauer D, Stone K, Strohmeier S, Simon V, Abreg J, Reich DL, Krammer F, Cardon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science 370:1227–1230. https://doi.org/10.1126/science.abb7728.

31. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Bodmercher CR, Rawlings SA, Sutherland A, Premkumar J, Ladi RS, Marrama D, de Silva AM, Frazier A, Carlin AF, Greenbaum JA, Peters B, Krammer F, Smith DM, Crotty S, Sette A. 2020. Targets of T-cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181:1489–1501.e15. https://doi.org/10.1016/j.cell.2020.05.015.

32. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, Deinjirattisai W, Rostron T, Saphire O, Avila H, Nakajima S, c-101:07. https://doi.org/10.1126/sciimmunol.abe0240.

33. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S, Naik HM, Betenbaugh MJ, Shrestha R, Wu AA, Hughes RM, Burgess I, Caturegili P, Laeyendecker O, Quinn TC, Sullivan D, Shoham S, Redd AD, Bloch EM, Casadevall A, Tobian AA. 2020. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 130:6141–6150. https://doi.org/10.1172/JCI142004.

34. Iyer AS, Jones FK, Dodoussiani A, Kelly M, Becker M, Slater D, Mills R, Teng E, Kamruzzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S, Ateyoe C, Ifrathie AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC. 2020. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 5:eabe0367. https://doi.org/10.1126/sciimmunol.abe0367.

35. Seow J, Graham C, Merrick A, Acors S, Pickering S, Steel KJA, Hemming O, O’Byrne A, Koupouh N, Galao RP, Betancor G, Wilson HD, Signell AW, Winsett H, Kerridge C, Huetter I, Jimenez-Guardeno J, Lista MJ, Temperton N, Snell LB, Bisnauthisingh K, Moore A, Green A, Martinez L, Stokes B, Honey J, Izquierdo-Barras A, Arbane G, Patel A, Tan MK, O’Connell L, O’Hara G, Mahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doorres KJ. 2020. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5:1598–1607. https://doi.org/10.1038/s41564-020-0813-8.

36. Chen Y, Zuiiani A, Fischinger S, Mullur J, Ateyoe C, Travers M, Lelli FJN, Pullen KM, Martin H, Tong P, Gautam A, Habibi S, Bensko J, Gakpo D, Feldman J, Hauser BM, Caradonna TM, Cai Y, Burke JS, Lin J, Lederer JA, Cordingley L, Pavlakis NG, Kim PS, O’Connor L, O’Hara G, Mahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doorres KJ. 2020. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 in UK convalescent individuals following COVID-19. Nat Immunol 21:1336–1345. https://doi.org/10.1038/s41556-020-0782-6.

37. Chen Y, Zuiiani A, Fischinger S, Mullur J, Ateyoe C, Travers M, Lelli FJN, Pullen KM, Martin H, Tong P, Gautam A, Habibi S, Bensko J, Gakpo D, Feldman J, Hauser BM, Caradonna TM, Cai Y, Burke JS, Lin J, Lederer JA, Cordingley L, Pavlakis NG, Kim PS, O’Connor L, O’Hara G, Mahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doorres KJ. 2020. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5:1598–1607. https://doi.org/10.1038/s41564-020-0813-8.

38. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, Chng MHY, Redd AD, Bloch EM, Casadevall A, Tobian AA. 2020. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 130:6141–6150. https://doi.org/10.1172/JCI142004.

39. Mateus J, Grifoni A, Karite A, Sridevi J, Ramirez SI, Dan JM, Burger ZC, Rawlings SA, Smith DM, Phillips E, Mailal S, Lammers M, Rubio P, Qi Li H, Luan D, Arts K, Mulder E, Kamarzaman M, Garcia-Beltran WF, Astudillo M, Yang D, Miller TE, Oliver E, Fischinger S, Ateyoe C, Ifrathie AJ, Calderwood SB, Lauer SA, Yu J, Li Z, Feldman J, Hauser BM, Caradonna TM, Branda JA, Turbett SE, LaRocque RC, Mellon G, Barouch DH, Schmidt AG, Azman AS, Alter G, Ryan ET, Harris JB, Charles RC. 2020. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol 5:eabe0367. https://doi.org/10.1126/sciimmunol.abo0120.

40. Chen Y, Zuiiani A, Fischinger S, Mullur J, Ateyoe C, Travers M, Lelli FJN, Pullen KM, Martin H, Tong P, Gautam A, Habibi S, Bensko J, Gakpo D, Feldman J, Hauser BM, Caradonna TM, Cai Y, Burke JS, Lin J, Lederer JA, Cordingley L, Pavlakis NG, Kim PS, O’Connor L, O’Hara G, Mahon E, Douthwaite S, Nebbia G, Batra R, Martinez-Nunez R, Shankar-Hari M, Edgeworth JD, Neil SJD, Malim MH, Doorres KJ. 2020. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 5:1598–1607. https://doi.org/10.1038/s41564-020-0813-8.

41. Roltgen K, Powell AE, Wirz OF, Stevens BA, Hogan CA, Njeim J, Hunter M, Wang H, Sahoo MK, Huang C, Yamamoto F, Manohar M, Manalac J, Otrelo-Cardoso AR, Pham TD, Rustagi A, Rogers AJ, Shah NH, Blish CA, Cochran JR, Jardetzky TS, Zehnder JL, Wang TT, Narasimhan B, Gombor S, Tibshirani R, Nadeau KC, Kim PS, Pinsky BA, Boyd SD. 2020. Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol 5:eabe0240. https://doi.org/10.1126/sciimmunol.abo0120.

42. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF, Sahi V, Figueroa A, Guo XV, Cerutti G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen KF, Kwong PD, Soderstro JG, Yin MT, Sheng Z, Huang Y, Shapiro L, Ho DD. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. Nature 584:450–456. https://doi.org/10.1038/s41586-020-2550-z.

43. Klein SL, Pekosz A, Park HS, Ursin RL, Shapiro JR, Benner SE, Littlefield K, Kumar S, Naik HM, Betenbaugh MJ, Shrestha R, Wu AA, Hughes RM, Burgess I, Caturegili P, Laeyendecker O, Quinn TC, Sullivan D, Shoham S, Redd AD, Bloch EM, Casadevall A, Tobian AA. 2020. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest 130:6141–6150. https://doi.org/10.1172/JCI142004.